News

Hosted on MSN3mon
FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to ... neuroscience leader with the drug’s manufacturer, Johnson & Johnson, said in a news release.
Hosted on MSN1mon
FDA Approves Nasal Spray for Depression
The U.S. Food and Drug Administration (FDA) has approved the use of a nasal spray as a standalone treatment ... the manufacturer Johnson & Johnson said in a press release. The study found that ...
pharmaphorum6d
FDA approves Janssen’s ketamine-based nasal antidepressant
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...
Yahoo Finance15d
FDA Approves Johnson & Johnson’s IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval ... this approval in Johnson & Johnson’s news ...
Mint14d
US FDA approves Johnson & Johnson's drug for immune-mediated disorder
Health care giantJohnson & Johnson said on Wednesday the US Food and Drug Administration (FDA) has approved its drug ... felt primarily within the company's medical technology unit, which makes ...
manilatimes14d
FDA Approves Johnson & Johnson's IMAAVYTM (nipocalimab-aahu) a New Treatment for Myasthenia Gravis (MG), Offering Hope for Families
New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY TM ... Learn more about this approval in ...